Enhua pharmaceutical's aripiprazole is expected to be approved for production within the year of on-site inspection this month

According to the information on July 15 on the website of the State Food and Drug Administration (CFDA), Enhua pharmaceutical's aripiprazole APIs and preparations will enter the site for inspection this month Industry insiders expect the product to be approved for production within this year Aripiprazole is a new type of atypical antipsychotic drug, which was listed in China in 2004 Due to the remarkable curative effect on the positive and negative symptoms of schizophrenia, the products grow rapidly after being put on the market The compound growth rate of the drug was 41.16% in 2006-2010, and the domestic market scale was about 400 million by 2010 According to CFDA, at present, Zhejiang Otsuka, Chengdu Kanghong and Chinese and Western pharmaceutical enterprises have obtained approval documents for pharmaceutical production At the same time, in addition to the Enhua pharmaceutical industry, there are also enterprises such as Huahai Pharmaceutical (600521 SH), Qilu pharmaceutical and hausen pharmaceutical in R & D Enhua pharmaceutical industry is the leader of central nervous system medicine in China Last year, the company's main products, midazolam and risperidone, were affected by the administrative price cut, which slowed down the company's industrial growth The market hopes that the company's reserve varieties will be approved for listing and create new performance growth points.